[(1S,2S,4R,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 3-hydroxy-2-phenylpropanoate;bromide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: [(1S,2S,4R,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 3-hydroxy-2-phenylpropanoate;bromide
• 化学式: C18H24BrNO4
• 分子量: 398.3
• InChiKey: CXYRUNPLKGGUJF-ODDNLWGVSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.93
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  59.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PREVENTIVE AND/OR REMEDY FOR HAND AND FOOT SYNDROME
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP2554184A1

  公开（公告）日：2013-02-06

  The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior preventive and/or treatment effect against Hand-Foot Syndrome.

  可以提供由具有抗胆碱能活性的化合物组成的预防和/或治疗手足综合征的制剂。由具有抗胆碱能活性的化合物组成的预防和/或治疗手足综合征的制剂可安全地用于手足综合征患者，并显示出对手足综合征具有卓越的预防和/或治疗效果。
• CINNAMATE SALTS OF A BETA-2 ADRENERGIC AGONIST
  申请人：GLAXO GROUP LIMITED

  公开号：EP1846374A1

  公开（公告）日：2007-10-24
• TREATMENT OF NEUROLOGICAL DISORDERS USING HUPERZINE
  申请人：President and Fellows of Harvard College

  公开号：EP2328584A2

  公开（公告）日：2011-06-08
• Treatment Of Neurological Disorders Using Huperzine
  申请人：Schachter Steven C.

  公开号：US20110224245A1

  公开（公告）日：2011-09-15

  Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and/or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.
• PREVENTIVE AND/OR THERAPEUTIC AGENT OF HAND-FOOT SYNDROME
  申请人：Ishizaka Kazuhiro

  公开号：US20130045956A1

  公开（公告）日：2013-02-21

  The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be provided. The agent for the prevention and/or treatment of Hand-Foot Syndrome comprising a compound with anticholinergic activity can be safely administered to the patients with Hand-Foot Syndrome, and has shown the superior preventive and/or treatment effect against Hand-Foot Syndrome.